Access the full text.
Sign up today, get DeepDyve free for 14 days.
Visit SAGE journals online journals
(2017)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016, 71
Shruti Guhasarkar, P. More, R. Banerjee (2017)
Urothelium‐adherent, ion‐triggered liposome‐in‐gel system as a platform for intravesical drug deliveryJournal of Controlled Release, 245
(1999)
Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model, 81
B. Friedman, Y. Dekel, A. Tubaro, A. Sidi, B. Shalva, J. Baniel, D. Kedar, L. Colombo, Dov Engelshtein, E. Fridman, Ifat Klein, Michal Jeshurun, Baruch Nerotski, Dima Zolotrayov, Nadav Malchi, J. Redorta, G. Wirth, I. Leibovitch, F. Witjes (2016)
PD11-05 THE CHEMOABLATIVE EFFECT OF VESIGEL INSTILLATION IN PATIENTS WITH NMIBC – PRELIMINARY RESULTSThe Journal of Urology, 195
(2013)
A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guerin in the treatment of bladder cancer, 34
(1991)
Pharmacodynamics of mitomycin C in cultured human bladder tumors, 51
(2012)
Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system, 4
M. Babjuk, M. Burger, R. Zigeuner, S. Shariat, B. Rhijn, E. Compérat, R. Sylvester, E. Kaasinen, A. Böhle, J. Redorta, M. Rouprêt (2013)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.European urology, 64 4
(2017)
Sustained-release formulation of mitomycin C to the upper urinary tract using a thermosensitive polymer: a preclinical study, 99
M. Babjuk, A. Böhle, M. Burger, O. Čapoun, D. Cohen, E. Compérat, V. Hernández, E. Kaasinen, J. Palou, M. Rouprêt, B. Rhijn, S. Shariat, V. Soukup, R. Sylvester, R. Zigeuner (2017)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.European urology, 71 3
Samantha Cambier, R. Sylvester, L. Collette, P. Gontero, M. Brausi, G. Andel, W. Kirkels, F. Silva, W. Oosterlinck, S. Prescott, Z. Kirkali, P. Powell, T. Reijke, L. Turkeri, S. Collette, J. Oddens (2016)
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.European urology, 69 1
(2008)
Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy, 101
(2009)
Experimental rat bladder urothelial cell carcinoma models, 27
(2014)
A floating hydrogel system capable of generating CO2 bubbles to diminish urinary obstruction after intravesical instillation, 31
(2017)
Urothelium-adherent, ion-triggered liposome-in-gel system as a platform for intravesical drug delivery, 245
Ke Men, Wei Liu, Lin Li, Xingmei Duan, Pan Wang, M. Gou, Xiawei Wei, Xiang Gao, Bi-lan Wang, Yanan Du, Meijuan Huang, Lijuan Chen, Z. Qian, Yuquan Wei (2012)
Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.Nanoscale, 4 20
Tingsheng Lin, Yifan Zhang, Jinhui Wu, Xiaozhi Zhao, Hui-bo Lian, Wei Wang, Hongqian Guo, Yiqiao Hu (2014)
A Floating Hydrogel System Capable of Generating CO2 Bubbles to Diminish Urinary Obstruction After Intravesical InstillationPharmaceutical Research, 31
H. Arentsen, K. Hendricksen, E. Oosterwijk, J. Witjes (2009)
Experimental rat bladder urothelial cell carcinoma modelsWorld Journal of Urology, 27
(2010)
An improved orthotopic rat bladder tumor model using Dil-loaded fluorescent AY-27 cells, 9
(2016)
The chemoablative effect of VesiGel® instillation in patients with NMIBC – preliminary results, 95
(2016)
EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin, 69
(2017)
Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: safety and feasibility, 35
Thomas Schmittgen, M. Wientjes, R. Badalament, J. Au (1991)
Pharmacodynamics of mitomycin C in cultured human bladder tumors.Cancer research, 51 15
N. Donin, D. Strauss‐Ayali, Y. Agmon-Gerstein, Nadav Malchi, A. Lenis, S. Holden, A. Pantuck, A. Belldegrun, K. Chamie (2017)
Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.Urologic oncology, 35 5
Dong Zhang, Peng Sun, Peng Li, Aibing Xue, Xiaokai Zhang, Haiyang Zhang, Xunbo Jin (2013)
A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Guérin in the treatment of bladder cancer.Biomaterials, 34 38
N. Donin, S. Duarte, A. Lenis, R. Caliliw, C. Torres, A. Smithson, D. Strauss‐Ayali, Y. Agmon-Gerstein, Nadav Malchi, J. Said, S. Raman, S. Holden, A. Pantuck, A. Belldegrun, K. Chamie (2017)
Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.Urology, 99
Ching-Wen Liu, Yu-Tse Wu, Kai-Jen Lin, Tsan‐Jung Yu, Yu-Liang Kuo, Li-Ching Chang (2016)
A Hydrogel-Based Epirubicin Delivery System for Intravesical ChemotherapyMolecules, 21
(2011)
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables, 60
Joachm Vandepitte, Jan Maes, B. Cleynenbreugel, H. Poppel, E. Lerut, P. Agostinis, P. Witte (2010)
An improved orthotopic rat bladder tumor model using DiI-loaded fluorescent AY-27 cellsCancer Biology & Therapy, 9
E. Bruijn, H. Sleeboom, P. Helsdingen, A. Oosterom, U. Tjaden, R. Maes (1992)
Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling timesInternational Journal of Cancer, 51
H. Arentsen, K. Hendricksen, C. Kaa, G. Reddy, E. Oosterwijk, J. Witjes (2012)
The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations.Urologic oncology, 30 1
K. Hendricksen, J. Molkenboer-Kuenen, E. Oosterwijk, C. Kaa, J. Witjes (2008)
Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopyBJU International, 101
(2016)
A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy, 21
(1992)
Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times, 51
S. Crooke, M. Henderson, M. Samson, L. Baker (1976)
Phase I study of oral mitomycin C.Cancer treatment reports, 60 11
(2012)
The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations, 30
J. Fernández-Gómez, R. Madero, E. Solsona, M. Unda, L. Martínez-Piñeiro, A. Ojea, J. Portillo, M. Montesinos, Marcelino González, C. Pertusa, J. Rodríguez-Molina, J. Camacho, M. Rabadán, A. Astobieta, S. Isorna, P. Muntañola, A. Gimeno, M. Blas, J. Martinez-Pineiro (2011)
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.European urology, 60 3
Z. Xiao, T. McCallum, K. Brown, Gerald Miller, S. Halls, I. Parney, Ronald Moore (1999)
Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour modelBritish Journal of Cancer, 81
Background: We investigated a thermoreversible hydrogel that is highly viscous at body temperature, while fluid-like at a low temperature, thus aiming for a slow and prolonged intravesical drug release. Our study purposed to assess antitumor efficacy of mitomycin C (MMC) mixed with hydrogel in an orthotopic rat bladder cancer model. Methods: Bladders of female Fischer F344 rats were grafted with 1.5 × 106 AY-27 urothelial carcinoma cells. On day 5, tumor presence was assessed by cystoscopy and rats were divided into six groups (five treatment, one control, n = 10/group). Intravesical treatments (0.5 mg or 1 mg MMC-H2O or MMC-hydrogel, or 2 mg MMC-hydrogel) were administered on days 5, 8 and 11. Rats were sacrificed at day 14 and bladders were evaluated. Results: Rats with tumor at cystoscopy (47/60) were evaluated for efficacy. At necropsy, all control animals (8/8) had tumors. No microscopic tumors were present in the 0.5 mg and 1 mg MMC-hydrogel groups compared with 2/8 and 1/8 rats in the 0.5 mg and 1 mg MMC-H2O groups (p = 0.47 and p = 1.00, respectively). Greater toxicity was seen in animals treated with MMC-hydrogel compared with MMC-H2O, as demonstrated by lower body weights at necropsy (p = 0.000) and a tendency for more severe clinical signs in the 1 and 2 mg MMC-hydrogel groups. Rats that died prematurely received 1 mg (4/10) or 2 mg (9/10) of MMC-hydrogel. Conclusions: Under the current model conditions it is unclear whether instillation of MMC-hydrogel is more effective than MMC-H2O. Nonetheless, the observed difference in toxicity, acting as a surrogate marker for systemic MMC exposure in the MMC-hydrogel-treated rats, supports the prolonged drug release mechanism of the hydrogel.
Therapeutic Advances in Urology – SAGE
Published: Mar 19, 2018
Keywords: animal models; bladder cancer; mitomycin C; thermosensitive hydrogel; urinary bladder neoplasms
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.